Pemetrexed-induced pneumonitis: A case report

Yohann Loriot; Charles Ferte; Carlos Gomez-Roca; Christian Moldovan; Ratislav Bahleda; Marie Wislez; Jacques Cadranel; Jean Charles Soria

doi:10.3816/CLC.2009.n.050

Pemetrexed-induced pneumonitis: A case report

Yohann Loriot, Charles Ferte, Carlos Gomez-Roca, Christian Moldovan, Ratislav Bahleda, Marie Wislez, Jacques Cadranel, Jean Charles Soria

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology. Herein, we report a case of pemetrexedinduced pneumonitis. Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.

Original language	English
Pages (from-to)	364-366
Number of pages	3
Journal	Clinical Lung Cancer
Volume	10
Issue number	5
DOIs	https://doi.org/10.3816/CLC.2009.n.050
Publication status	Published - 1 Jan 2009

Keywords

Erlotinib
Interstitial pneumonitis
Non-small-cell lung cancer

Access to Document

10.3816/CLC.2009.n.050

Cite this

@article{d2580b49fffa4d91805e9de247368af1,

title = "Pemetrexed-induced pneumonitis: A case report",

abstract = "Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology. Herein, we report a case of pemetrexedinduced pneumonitis. Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.",

keywords = "Erlotinib, Interstitial pneumonitis, Non-small-cell lung cancer",

author = "Yohann Loriot and Charles Ferte and Carlos Gomez-Roca and Christian Moldovan and Ratislav Bahleda and Marie Wislez and Jacques Cadranel and Soria, {Jean Charles}",

year = "2009",

month = jan,

day = "1",

doi = "10.3816/CLC.2009.n.050",

language = "English",

volume = "10",

pages = "364--366",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "5",

}

TY - JOUR

T1 - Pemetrexed-induced pneumonitis

T2 - A case report

AU - Loriot, Yohann

AU - Ferte, Charles

AU - Gomez-Roca, Carlos

AU - Moldovan, Christian

AU - Bahleda, Ratislav

AU - Wislez, Marie

AU - Cadranel, Jacques

AU - Soria, Jean Charles

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology. Herein, we report a case of pemetrexedinduced pneumonitis. Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.

AB - Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology. Herein, we report a case of pemetrexedinduced pneumonitis. Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.

KW - Erlotinib

KW - Interstitial pneumonitis

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77249160257&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.050

DO - 10.3816/CLC.2009.n.050

M3 - Article

AN - SCOPUS:77249160257

SN - 1525-7304

VL - 10

SP - 364

EP - 366

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 5

ER -

Pemetrexed-induced pneumonitis: A case report

Abstract

Keywords

Access to Document

Other files and links

Cite this